ClinicalTrials.gg
CompletedNCT03358875RATIONALE-303Updated Feb 10, 2025Results posted

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Tislelizumab and Docetaxel in Non-small Cell Lung Cancer, sponsored by BeiGene. Completed at 121 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
805
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 41
805 · median 39
Started
2017
the only one that year
Phase 3
9 of 41
none open now
Registered
1st of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is the only one that started in 2017, is one of 9 in phase 3, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.

Read the detailed description

This is a randomized, open-label, multicenter Phase 3 study in adult participants with histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Signed Form.
  3. confirmed locally advanced or (Stage IIIB or IV) NSCLC of either squamous or non-squamous histology types with disease progression during or following treatment with at least one platinum-containing regimen, but no more than 2 .
  4. Participants must be able to provide fresh or archival tumor tissues for central assessment of expression in tumor cells. Participants with non-squamous histology must provide evidence of not harboring sensitizing epidermal growth factor (EGFR) mutation tested by a histology-based method.
  5. (ECOG) performance status ≤ 1.
  6. Adequate hematologic and end-organ function.
  7. Expected life span > 12 weeks.
  8. Willing to be compliance with requirement during pre-specified study participating period

Key Exclusion Criteria:

  1. Prior therapies of docetaxel or treatment targeting programmed cell death protein 1 (PD-1), PD-L1 or cytotoxic T-lymphocyte associated protein 4 (CTLA-4).
  2. Harboring EGFR sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation.
  3. Unresolved side effects of Grade 2 and above from prior anti-cancer therapies, except for adverse events (AEs) not constituting a likely safety risk (e.g. alopecia, rash, pigmentation, specific lab abnormalities).
  4. History of severe reactions to other monoclonal antibodies (mAbs).
  5. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.
  6. With uncontrollable pleural effusion, pericardial effusion, or ascites requiring interventional treatment.
  7. Active or uncontrolled, untreated .
  8. Severe chronic or active infection requiring systemic treatment.
  9. Known (HIV) infection, participants with untreated chronic , active vaccination treatment.
  10. Insufficient cardiac functions and other underlying unfavorable cardiovascular conditions.
  11. Prior stem cell transplantation or organ transplantation.
  12. Active diseases or history of autoimmune diseases that may relapse.
  13. With conditions requiring systemic treatment with either (>10 mg daily prednisone or equivalent) or other medications.
  14. With severe underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse that may affect the explanation of drug toxicity or AEs or result in impaired compliance with study conduct.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
805 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

    Drug: Tislelizumab

  • Active comparator
    Docetaxel

    Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

    Drug: Docetaxel

Interventions

  • Tislelizumab administered by intravenous (IV) infusion

    Also known as: BGB-A317, TEVIMBRA®

  • Docetaxel administered as an IV infusion over 1 hour

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in All Participants (Co-primary Endpoint)

    OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.

    Time frame: From randomization to the data cutoff date of 10 August 2020; up to 32.4 months

  2. Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)

    OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

Secondary outcomes

  1. Objective Response Rate (ORR) in All Participants

    Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  2. Objective Response Rate in PD-L1-Positive Participants

    Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  3. Duration of Response (DOR) for All Responders

    DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  4. Duration of Response (DOR) in PD-L1-Positive Responders

    DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  5. Progression-free Survival (PFS) in All Participants

    PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  6. Progression-free Survival in PD-L1 Positive Participants

    PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

  7. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and two global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS/QoL score indicates better quality of life.

    Time frame: Baseline and Cycle 6 (each cycle was 3 weeks)

  8. Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores

    The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.

    Time frame: Baseline and Cycle 6 (each cycle was 3 weeks)

  9. Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)

    The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline and Cycle 6 (each cycle was 3 weeks)

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. The investigator assessed the severity of each AE and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 as defined below: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. * Grade 3: Severe or medically significant but not immediately life threatening. hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living. * Grade 4: Life threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

    Time frame: From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 18 January 2024 (up to approximately 63 months)

07

Results

Posted Feb 10, 2025

Participant flow

This study was conducted at 109 study centers in 10 countries (China, Brazil, Bulgaria, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, and Turkey).

Participant flow — Overall Study
MilestoneTislelizumabDocetaxel
Started535270
Received treatment534258
Completed00
Not completed535270
Withdrew: Death409223
Withdrew: Study closed by sponsor6629
Withdrew: Withdrawal by subject1316
Withdrew: Lost to follow-up132
Withdrew: Miscellaneous330
Withdrew: Remained on study10

Outcome measures

PrimaryOverall Survival (OS) in All Participants (Co-primary Endpoint)

OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.

Time frame:
From randomization to the data cutoff date of 10 August 2020; up to 32.4 months
Reported as:
Median · months
Overall Survival (OS) in All Participants (Co-primary Endpoint)
monthsTislelizumabDocetaxel
Overall Survival (OS) in All Participants (Co-primary Endpoint)17.2 (15.28 to 20.04)11.9 (10.18 to 13.93)
Statistical analysis
  • Tislelizumab vs Docetaxel · 1-sided Log Rank Test · p = <0.0001 (OS in the ITT population was tested at one-sided p value boundary of 0.0120.) · Hazard ratio (hr): 0.64 · 95% CI 0.527 to 0.778A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% confidence interval (CI).
PrimaryOverall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)

OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Median · months
Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)
monthsTislelizumabDocetaxel
Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)19.3 (16.49 to 22.60)11.5 (8.15 to 13.54)
Statistical analysis
  • Tislelizumab vs Docetaxel · 1-sided Log Rank Test · p = <0.0001 (OS in the PD-L1 positive analysis set was tested at the one-sided p-value boundary of 0.025.) · Hazard ratio (hr): 0.53 · 95% CI 0.407 to 0.702Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).
SecondaryObjective Response Rate (ORR) in All Participants

Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in All Participants
percentage of participantsTislelizumabDocetaxel
Objective Response Rate (ORR) in All Participants22.6 (19.14 to 26.40)7.0 (4.29 to 10.77)
Statistical analysis
  • Tislelizumab vs Docetaxel · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.86 · 95% CI 2.336 to 6.393Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology, line of therapy, and PDL1 expression.
SecondaryObjective Response Rate in PD-L1-Positive Participants

Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Number · percentage of participants
Objective Response Rate in PD-L1-Positive Participants
percentage of participantsTislelizumabDocetaxel
Objective Response Rate in PD-L1-Positive Participants37.4 (31.13 to 44.09)7.0 (3.05 to 13.25)
Statistical analysis
  • Tislelizumab vs Docetaxel · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 8.04 · 95% CI 3.721 to 17.379Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology and line of therapy.
SecondaryDuration of Response (DOR) for All Responders

DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Median · months
Duration of Response (DOR) for All Responders
monthsTislelizumabDocetaxel
Duration of Response (DOR) for All Responders13.5 (8.54 to 19.58)6.0 (2.10 to 7.16)
Statistical analysis
  • Tislelizumab vs Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.31 · 95% CI 0.176 to 0.536A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI.
SecondaryDuration of Response (DOR) in PD-L1-Positive Responders

DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Median · months
Duration of Response (DOR) in PD-L1-Positive Responders
monthsTislelizumabDocetaxel
Duration of Response (DOR) in PD-L1-Positive Responders11.9 (8.31 to 19.58)4.2 (0.56 to 6.05)
Statistical analysis
  • Tislelizumab vs Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.16 · 95% CI 0.066 to 0.370A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI.
SecondaryProgression-free Survival (PFS) in All Participants

PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Median · months
Progression-free Survival (PFS) in All Participants
monthsTislelizumabDocetaxel
Progression-free Survival (PFS) in All Participants4.2 (3.88 to 5.52)2.6 (2.17 to 3.78)
Statistical analysis
  • Tislelizumab vs Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.63 · 95% CI 0.528 to 0.745A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI.
SecondaryProgression-free Survival in PD-L1 Positive Participants

PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Reported as:
Median · months
Progression-free Survival in PD-L1 Positive Participants
monthsTislelizumabDocetaxel
Progression-free Survival in PD-L1 Positive Participants6.5 (6.24 to 8.28)2.5 (2.10 to 4.11)
Statistical analysis
  • Tislelizumab vs Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.38 · 95% CI 0.285 to 0.494A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% confidence interval (CI).
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and two global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS/QoL score indicates better quality of life.

Time frame:
Baseline and Cycle 6 (each cycle was 3 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score
score on a scaleTislelizumabDocetaxel
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score2.4 (0.62 to 4.12)-3.4 (-6.45 to -0.27)
Statistical analysis
  • Tislelizumab vs Docetaxel · Mixed Models Analysis · p = 0.0008 · Least squares (ls) mean difference: 5.7 · 95% CI 2.38 to 9.07
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores

The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.

Time frame:
Baseline and Cycle 6 (each cycle was 3 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores
score on a scaleTislelizumabDocetaxel
Coughing Scale-7.8 (-10.23 to -5.30)0.5 (-3.87 to 4.87)
Dyspnoea Scale-1.2 (-2.93 to 0.56)2.0 (-1.01 to 5.05)
Chest Pain Scale-0.9 (-2.86 to 1.06)1.3 (-2.15 to 4.84)
Statistical analysis
  • Tislelizumab vs Docetaxel · Mixed Models Analysis · p = 0.0007 · Ls mean difference: -8.3 · 95% CI -13.02 to -3.51
  • Tislelizumab vs Docetaxel · Mixed Models Analysis · p = 0.0579 · Ls mean difference: -3.2 · 95% CI -6.52 to 0.11
  • Tislelizumab vs Docetaxel · Mixed Models Analysis · p = 0.2472 · Ls mean difference: -2.2 · 95% CI -6.05 to 1.56
SecondaryChange From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)

The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline and Cycle 6 (each cycle was 3 weeks)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
score on a scaleTislelizumabDocetaxel
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)1.0 ± 11.891.7 ± 11.36
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. The investigator assessed the severity of each AE and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 as defined below: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. * Grade 3: Severe or medically significant but not immediately life threatening. hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living. * Grade 4: Life threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

Time frame:
From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 18 January 2024 (up to approximately 63 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTislelizumabDocetaxel
Any TEAE518254
≥ Grade 3 TEAE233193

Adverse events

Collected over All-cause mortality is reported from randomization up to study completion date cut-off date of 18 January 2024, up to 63 months. AEs are reported from first dose of study drug to 30 days after last dose, up to study completion date cut-off date of 18 January 2024, up to 63 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab409/535 (76.4%)192/534 (36%)498/534 (93.3%)
Docetaxel223/270 (82.6%)84/258 (32.6%)246/258 (95.3%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventTislelizumabDocetaxel
Febrile neutropeniaBlood and lymphatic system disorders0/53421/258
PneumoniaInfections and infestations39/53419/258
NeutropeniaBlood and lymphatic system disorders0/53411/258
Neutrophil count decreasedInvestigations0/5348/258
PneumonitisRespiratory, thoracic and mediastinal disorders15/5340/258
LeukopeniaBlood and lymphatic system disorders0/5346/258
AnaemiaBlood and lymphatic system disorders2/5345/258
DyspnoeaRespiratory, thoracic and mediastinal disorders8/5345/258
Pleural effusionRespiratory, thoracic and mediastinal disorders9/5345/258
HaemoptysisRespiratory, thoracic and mediastinal disorders10/5344/258
Most frequent other events
Showing 10 of 74
Most frequent other events
EventTislelizumabDocetaxel
AlopeciaSkin and subcutaneous tissue disorders7/534127/258
AnaemiaBlood and lymphatic system disorders156/534114/258
Neutrophil count decreasedInvestigations17/53490/258
White blood cell count decreasedInvestigations21/53475/258
NeutropeniaBlood and lymphatic system disorders10/53473/258
LeukopeniaBlood and lymphatic system disorders17/53470/258
Decreased appetiteMetabolism and nutrition disorders88/53462/258
AstheniaGeneral disorders76/53457/258
Alanine aminotransferase increasedInvestigations112/53439/258
CoughRespiratory, thoracic and mediastinal disorders111/53440/258

Baseline characteristics

Age, Continuous
Age, Continuous(years)TislelizumabDocetaxelTotal
Mean60.4 ± 8.7960.7 ± 8.9560.5 ± 8.84
Sex: Female, Male
Sex: Female, Male(Participants)TislelizumabDocetaxelTotal
Female11964183
Male416206622
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TislelizumabDocetaxelTotal
American Indian or Alaska Native12113
Asian424219643
Black or African American134
Native Hawaiian or Other Pacific Islander336
White9344137
Other202
Histology
Histology(Participants)TislelizumabDocetaxelTotal
Squamous248122370
Non-Squamous287148435
Current Line of Therapy
Current Line of Therapy(Participants)TislelizumabDocetaxelTotal
Second line453229682
Third line8241123
PD-L1 Expression
PD-L1 Expression(Participants)TislelizumabDocetaxelTotal
≥ 25% of tumor cells227115342
< 25% of tumor cells307152459
Missing134
Smoking Status
Smoking Status(Participants)TislelizumabDocetaxelTotal
Never16282244
Current502070
Former323168491
08

Study locations

121 sites
  • Hospital de Amor Barretos
    Barretos, 14784-400, Brazil
  • Hospital Evangelico de Cachoeiro de Itapemirim
    Cachoeiro de Itapemirim, 29308-020, Brazil
  • Hospital Haroldo Juacaba Instituto Do Cancer Do Ceara
    Fortaleza, 60430-230, Brazil
  • Oncosite Centro de Pesquisa Clinica Em Oncologia
    Ijui, 98700-000, Brazil
  • Fundacao Doutor Amaral Carvalho
    Jau, 17210-120, Brazil
  • Hospital Bruno Born
    Lajeado, 95900-000, Brazil
  • Hospital Sao Vicente de Paulo
    Passo Fundo, 99010-080, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto AlegreRS, 900350-903, Brazil
  • Hgb Hospital Giovanni Battista Mae de Deus Center
    Porto Alegre, 90470-340, Brazil
  • Hospital Sao Lucas Da Pucrs
    Porto Alegre, 90610-000, Brazil
  • Hospital Nossa Senhora Da Conceicao
    Porto Alegre, 91350-200, Brazil
  • Inca Instituto Nacional de Cancer
    Rio de Janeiro, 20231-050, Brazil
  • Nob Nucleo de Oncologia Da Bahia
    Salvador, 40170-110, Brazil
  • Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
    Santo Andre, 09060-650, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
    Sao Paulo, 01246-000, Brazil
  • Umhat Deva Maria, Eood
    Burgas, 8000, Bulgaria
  • Mhat Dobrich, Ad
    Dobrich, 9300, Bulgaria
  • Mhat Dr Tota Venkova, Ad
    Gabrovo, 5300, Bulgaria
  • Complex Oncology Center Rousse Eood
    Rousse, 7000, Bulgaria
  • Mhat For Womens Health Nadezhda, Ood
    Sofia, 1330, Bulgaria
  • Acibadem City Clinic Mhat Tokuda Ead
    Sofia, 1407, Bulgaria
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing 101149, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing 400042, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Guangzhou Institute of Respiratory Disease
    Guangzhou, Guangdong 510120, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
  • The Affiliated Hospital of Zunyi Medical College
    Zunyi, Guizhou 563000, China
  • Hainan General Hospital
    Haikou, Hainan 570206, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Nantong Tumor Hospital Branch North
    Nantong, Jiangsu 226000, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221000, China
  • Jiangxi Province Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shaanxi 710061, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    Chengdu, Sichuan 610071, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Tianjin Union Medical Center (Nankai University Affiliated Hospital)
    Tianjin, Tianjin 300121, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830054, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics Branch Oncology Hospital
    Kaunas, 45427, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, 50103, Lithuania
  • National Cancer Institute
    Vilnius, 8660, Lithuania
  • Health Pharma Professional Research Sa de Cv
    Ciudad de Mexico, 03100, Mexico
  • Investigacion Onco Farmaceutica (Oncotech)
    La Paz, 23040, Mexico
  • Fundacion Rodolfo Padilla Padilla, Ac
    Leon, 37000, Mexico
  • Medica Sur
    Mexico, 14050, Mexico
  • Accelerium S de Rl de Cv
    Monterrey, 64000, Mexico
  • Centro de Investigacion Clinica Chapultepec Sa de Cv
    Morelia, 58260, Mexico
  • Oaxaca Site Management Organization Sc
    Oaxaca, 68000, Mexico
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Waikato Hospital
    Hamilton Waikato, 3204, New Zealand
  • Tauranga Hospital
    Tauranga, 3112, New Zealand
  • Szpital Specjalistyczny Brzeziny
    Brzeziny, 95-060, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Centrum Terapii Wspolczesnej Jm Jasnorzewska Sp Komandytowo Akcyjna
    Lodz, 90-242, Poland
  • Salve Medica Sp Z Oo, Sp Komandytowa
    Lodz, 91-211, Poland
  • Zespol Gruzlicy I Chorob Pluc W Olsztynie Oddz Onkologii Z Pododdz Chemioterapii Nowotworow Puc
    Olsztyn, 10-357, Poland
  • Mazowiecki Szpital Specjalistyczny W Ostrolece Im Dr Jozefa Psarskiego
    Ostroleka, 07-410, Poland
  • Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
    Otwock, 05-400, Poland
  • Izerskie Centrum Pulmonologii I Chemioterapii Izer Med Spolka Z Oo
    Szklarska Porba, 58-580, Poland
  • Centrum Onkologii Instytut Im M Sklodowskiej Curie
    Warszawa, 02-034, Poland
  • Arkhangelsk Regional Clinical Oncological Dispensary
    Arkhangelsk, Arkhangel'skaya Oblast' 163045, Russian Federation
  • Irkutsk Regional Oncology Dispensary
    Irkutsk, Irkutiskaya Oblast' 664035, Russian Federation
  • Fsbi of Higher Educationogarev Mordovia State University
    Saransk, Mordoviya, Respublika 430005, Russian Federation
  • N N Blokhin Russian Cancer Research Center Konstantin Laktionov
    Moscow, Moskva 115478, Russian Federation
  • Fsbi Russian Scientific Center of Radiology and Nuclear Medicine of the Moh of the Rf
    Moscow, Moskva 117837, Russian Federation
  • Vitamed Llc
    Moscow, Moskva 121309, Russian Federation
  • Bih of Omsk Region Clinical Oncology Dispensary
    Omsk, Omskaya Oblast' 644013, Russian Federation
  • Sbei Hpe Ryazan State Medical University Na Academician Ip Pavlov of the Moh of the Rf
    Ryazan, Ryazanskaya Oblast' 390026, Russian Federation
  • Private Medical Institution Evromedservis
    Pushkin, Sankt-Peterburg 7042, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    SaintPetersburg, Sankt-Peterburg 197022, Russian Federation
  • Llc Center of Palliative Medicine Devita
    SaintPetersburg, Sankt-Peterburg 197183, Russian Federation
  • Fsbi Clinical Research and Practical Center For Specialized Medical Care (Oncology)
    SanktPetersburg, Sankt-Peterburg 197758, Russian Federation

Showing the first 100 of 121 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29. PubMed 36184068 ↗
  • Huang D, Zhou C, Barnes G, Ma Y, Li S, Zhan L, Tang B. The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer. Cancer Med. 2023 Aug;12(16):17403-17412. doi: 10.1002/cam4.6361. Epub 2023 Aug 17. PubMed 37587845 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2021, 43 months.

Results were first posted in Feb 2025, 3 years 6 months after primary completion.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 43 months is above that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartActual
Nov 30, 2017
Primary completionActual
Jul 15, 2021
CompletionActual
Jan 18, 2024
Results first posted
Feb 10, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03358875
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Nov 30, 2017
Primary completion
Jul 15, 2021
Completion
Jan 18, 2024
Results posted
Feb 10, 2025
Last update
Feb 10, 2025

Study contacts

Caicun Zhou, PhD
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion